雲頂新耀大升超8%創近3個月新高,上半年收入環比大增158%至3.02億元,重申對全年7億元銷售目標有信心
雲頂新耀-B(1952.HK)盤初一度大升超8%至22.7港元,股價創6月5日以來新高。公司今早公佈業績顯示,2024年上半年總收入達3.02億元,較2023年下半年大幅增長158%,運營費用佔收入比重大幅減少249%,運營效率顯著提升;非國際財務準則虧損顯著收窄35%;剔除非現金項目後毛利率為83%,實現公司歷史上的首次商業化層面盈利。同時現金餘額仍十分充足,達19.3億元,為公司未來的業務發展和持續增長提供保障。2024年上半年,在商業化方面,公司腎科領域核心產品耐賦康®作為IgA腎病的唯一獲批對因治療藥物已在中國內地和新加坡成功商業化上市,並於中國香港獲批。另外,全球首個氟環素類抗菌藥物依嘉®,作為公司在中國的首個商業化產品,銷售增長勢頭強勁。與此同時,自身免疫領域的重磅藥物伊曲莫德在中國澳門及新加坡獲批。公司預計,到2024年底將有三款產品實現商業化上市。雲頂新耀對實現全年人民幣7億元的銷售目標非常有信心,併力爭在2025年底前實現現金盈虧平衡的戰略目標。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.